Quantcast
 
New ETF Book by Larry Connors - Click here to read more


 

Biophan Announces Issuance of Key US Patent

Thu. March 05, 2009; Posted: 07:00 AM
Stocks RSS

Look up the PowerRating of BIPH and see how it has performed over the past week as well as the current proprietary PowerRating.

PITTSFORD, NY, Mar 05, 2009 (MARKET WIRE via COMTEX) -- BIPH | Quote | Chart | News | PowerRating -- Biophan Technologies, Inc. (OTCBB: BIPH | Quote | Chart | News | PowerRating) (FRANKFURT: BTN), a developer of next-generation medical technology, announced today that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent No. 7,494,459, entitled "Sensor-Equipped and Algorithm Controlled Direct Mechanical Ventricular Assist Device." The patent covers important operational aspects of the Myotech Circulatory Support System (CSS) technology including critical control aspects of the drive unit.

The Myotech CSS is a novel, non-blood contacting circulatory support system consisting of a flexible polymer cup which is inserted via an incision between two ribs and is positioned around the lower half of the heart, avoiding direct contact with circulating blood, which is the primary cause of complications with competitive devices. An external drive unit actuates the CSS cup, providing active systolic and diastolic support. This design can be rapidly installed in less than five minutes. The speed of installation and lack of contact with circulating blood make the CSS a superior design for treating sudden cardiac arrest patients. Over 260,000 patients per year experience in hospital cardiac arrest in the US alone, and these patients could greatly benefit from this device.

The Company has pending application for additional patents that will cover future enhancements to the technology.

"We are excited by the issuance of this patent, which greatly increases the value of our technology portfolio," stated John Lanzafame, Biophan's CEO. "This patent is the first US patent to issue covering the Myotech CSS technology, and is an important milestone for us."

Biophan is currently seeking development and license partners to move the Myotech CSS forward into clinical trials. In addition, the Company has multiple grant applications under review at the National Institutes of Health and Department of Defense to help support research and development of the CSS technology.

About Biophan Technologies, Inc.

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is seeking development partners to commercialize the Myotech Circulatory Support System, which has significant potential to improve the treatment of acute heart failure. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expect, or believe may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact:
Biophan Technologies, Inc.
(585) 267-4800
Email Contact


SOURCE: Biophan Technologies, Inc.

http://www2.marketwire.com/mw/emailprcntct?id=45E09F60FC504ABF
For full details for BIPH click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Most Popular News
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.